Royalty Pharma Plc (RPRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $58.44 (-0.83%), Market cap $30.55B, P/E ratio 27.93, 52-week low–high $32.31 ~ $53.55.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Financial statements, price targets, institutional (13F) holdings and related news for Royalty Pharma Plc are updated in real time on BlackAll Trade.
Royalty Pharma Plc trades at $58.44 (-0.83%). Real-time quotes and charts are available on BlackAll Trade.
Royalty Pharma Plc has a market cap of about $30.55B. Its P/E ratio is 27.93.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approxim